CERS5

Across TCGA pan-cancer cohorts, CERS5 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CERS5 data layer compared with 27 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CERS5 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CERS5 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUAD, COAD, and LIHC are the cancer types where CERS5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.167	0.770	<.001	17	view →
COAD	OS	Median	All	0.001	0.871	<.001	12	view →
LIHC	DFS	Median	All	0.134	0.530	.022	6	view →
ESCA	DFS	Median	All	0.409	0.535	.047	2	view →
UCEC	DFS	Median	All	1.000	0.629	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CERS5–LUAD (DFS)

Open the LUAD breakdown →